Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 5/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560990 | 1.00 | PAM (0.71) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL560056 | 0.98 | PAM (0.74) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL560057 | 0.98 | PAM (0.74) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL3360904 | 0.86 | PAM (0.57) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL582727 | 0.84 | PAM (1.00) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL2148302 | 0.84 | PAM (1.00) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL156767 | 0.84 | PAM (1.00) | PAMMAOBHDAC3HDAC4HDAC1 | |
| SCHEMBL387249 | 0.82 | PAM (0.96) | PAMMAOBHDAC3HDAC4HDAC1 | |
| Ammonia Solution, Strong SCHEMBL6327623 | 0.82 | PAM (0.96) | PAMMAOBHDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL28759894 | 0.82 | PAM (0.96) | PAMMAOBHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | claimed |
| WO-2008011074-A2 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC (US) | 2008-01-24 | — | — | WO | claimed |
| US-7312247-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2007-12-25 | — | — | US | claimed |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | ERRANT GENE THERAPEUTICS, LLC | 2007-02-15 | — | — | US | claimed |
| EP-1408946-A4 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2004-06-09 | — | — | EP | claimed |
| EP-1408946-A2 | HISTONE DEACETYLASE INHIBITORS | Circagen Pharmaceutical (US) | 2004-04-21 | — | — | EP | claimed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | claimed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | claimed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | claimed |
| US-8420698-B2 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120035257-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-20110287535-A1 | Histone Deacetylase Inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | ERRANT GENE THERAPEUTICS, LLC | 2011-11-24 | — | — | US | disclosed |
| US-8026280-B2 | For therapy of cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. | ERRANT GENE THERAPEUTICS, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035257-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC11, HDAC9 | PAM 2503/4885MAOB 1386/4885HDAC3 6/4885 |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | PAM 2987/4885MAOB 3351/4885HDAC3 16/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | PAM 2447/4885MAOB 1639/4885HDAC3 7/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | PAM 3728/4885MAOB 2821/4885HDAC3 6/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | PAM 2693/4885MAOB 1235/4885HDAC3 5/4885 |
| US-20110288168-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC6, HDAC5 | PAM 2956/4885MAOB 1159/4885HDAC3 6/4885 |
| US-20070037869-A1 | Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid | HDAC5, HDAC1, ZNF277 | PAM 2576/4885MAOB 2002/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.